Dasiglucagon for (CHI)

In June 2017, Zealand obtained orphan drug designation from the European Commission for the use of our multiple-dose formulation of dasiglucagon for the treatment of CHI.

FDA granted orphan drug designation in August 2017. Newborns with CHI have persistent episodes of hypoglycemia and are at risk of developing brain damage and many will have to undergo major pancreatic surgery to prevent the hypoglycemic episodes.

Third party studies have demonstrated the potential of preventing persistent hypoglycemia in CHI by treatment with lyophilized glucagon reconstituted daily. Dasiglucagon could offer an attractive alternative to current standard of care with its potential to be infused subcutaneously via a pump.